Please visit answersincme.com/29264-replay860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Aditya Bardia, MD and Tiffany A. Traina, MD, FASCO. In this activity, experts in breast cancer share evidence-based insights on integrating current and emerging TROP2-directed antibody-drug conjugates (ADCs) into real-world triple-negative breast cancer (TNBC) care. Upon completion of this activity, participants should be better able to: Identify the role of TROP2-directed antibody-drug conjugates (ADCs) in metastatic triple-negative breast cancer (TNBC) treatment; Compare the latest clinical data on available and emerging TROP2-targeting ADCs for the first-line treatment of patients with TNBC; and Discuss evidence-based strategies to optimize the selection of appropriate patients for first-line treatment with TROP2-targeting ADCs.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related